サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1728604

病理学におけるAlの世界市場：オファリング別、ニューラルネットワーク別、機能別、ユースケース別、エンドユーザー別、地域別 - 2030年までの予測

Al in Pathology Market by Neural Network(GAN, CNN, RNN),Function(Diagnostic, Image Analysis, CDSS, Data Management, Analytics),Use Case(Drug Discovery, Clinical Workflow),End User(Hospitals, Labs, Pharma/Biotech), & Region-Global Forecast to 2030

出版日
ページ情報
英文 320 Pages
納期
即納可能 即納可能とは
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.91円
病理学におけるAlの世界市場：オファリング別、ニューラルネットワーク別、機能別、ユースケース別、エンドユーザー別、地域別 - 2030年までの予測
出版日: 2025年05月08日
発行: MarketsandMarkets
ページ情報: 英文 320 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の病理学におけるAIの市場規模は、予測期間中に26.5％の高いCAGRで拡大し、2025年の1億743万米ドルから2030年には3億4,739万米ドルに達すると予測されています。

The Personalized Medicine Coalition Report 2022によると、2023年にFDAは希少疾患患者のための16の新しい個別化治療を承認しました。新たに承認された治療法のうち、7つのがん治療薬と3つのその他の疾患・病態を対象とした治療薬があります。これら承認された個別化治療の約47％は、がん治療が適応でした。

調査範囲
調査対象年 2024年～2030年
基準年 2024年
予測期間 2024年～2030年
検討単位 金額（10億米ドル）
セグメント オファリング別、ニューラルネットワーク別、機能別、ユースケース別、エンドユーザー別、地域別
対象地域 北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカ

2024年、創薬セグメントは病理学におけるAl市場で最大のシェアを占めました。製薬＆バイオテクノロジーの研究開発費の活況、ハイスループット・スクリーニング＆イメージングの増加、疾患の特定＆分類のための病理画像解析におけるAIアルゴリズムの使用の増加、新規治療薬の開発を加速するAIの能力が市場を押し上げると予想されます。

2024年には、創薬・市場開拓の進展と薬毒物検査における病理学におけるAlの利用増加により、製薬・バイオ製薬企業セグメントが最大の市場シェアを占めました。バイオテクノロジー企業は、バイオバンク、バイオ医薬品研究、分子アッセイ、個別化医療の開発にAIベースのデジタル病理検査を利用しています。

2024年、北米が病理学におけるAl市場で最大の市場シェアを占めたのは、ハイテク機械の使用を可能にする研究開発と先進ヘルスケアインフラへの旺盛な投資によるものです。大規模な患者プールとデータの利用可能性は、より高い精度と効率のためにAIを訓練するために使用することができる大規模なデータベースを作成するのに役立ちます。

当レポートでは、世界の病理学におけるAl市場について調査し、オファリング別、ニューラルネットワーク別、機能別、ユースケース別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • イントロダクション
  • 市場力学
  • 顧客ビジネスに影響を与える動向と混乱
  • 業界動向
  • エコシステム分析
  • バリューチェーン分析
  • 技術分析
  • 規制状況
  • 価格分析
  • ポーターのファイブフォース分析
  • 特許分析
  • 主要な利害関係者と購入基準
  • エンドユーザー分析
  • 2025年～2026年の主な会議とイベント
  • ケーススタディ分析
  • 投資と資金調達のシナリオ
  • ビジネスモデル
  • 病理学におけるAl市場/GEN AIの影響
  • 貿易分析
  • 米国の2025年関税

第6章 病理学におけるAl市場、オファリング別

  • イントロダクション
  • エンドツーエンドソリューション
  • ニッチポイントソリューション
  • テクノロジー
  • ハードウェア
  • 顕微鏡
  • スキャナー
  • ストレージシステム

第7章 病理学におけるAl市場、ニューラルネットワーク別

  • イントロダクション
  • 畳み込みニューラルネットワーク（CNNS）
  • 生成的敵対ネットワーク（GANS）
  • リカレントニューラルネットワーク（RNNS）
  • その他

第8章 病理学におけるAl市場、機能別

  • イントロダクション
  • 画像解析
  • 診断
  • ワークフロー管理
  • データ管理
  • 予測分析
  • CDSS
  • 自動レポート生成
  • 品質保証ツール

第9章 病理学におけるAl市場、ユースケース別

  • イントロダクション
  • 創薬
  • 病気の診断と予後
  • 臨床ワークフロー
  • トレーニングと教育

第10章 病理学におけるAl市場、エンドユーザー別

  • イントロダクション
  • 製薬会社およびバイオ医薬品会社
  • 病院および検査機関
  • 学術研究機関

第11章 病理学におけるAl市場、地域別

  • イントロダクション
  • 北米
    • マクロ経済見通し
    • 米国
    • カナダ
  • 欧州
    • マクロ経済見通し
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • その他
  • アジア太平洋
    • マクロ経済見通し
    • 中国
    • 日本
    • インド
    • その他
  • ラテンアメリカ
    • マクロ経済見通し
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • マクロ経済見通し
    • GCC諸国
    • その他

第12章 競合情勢

  • イントロダクション
  • 主要参入企業の戦略/強み
  • 収益分析、2020年～2024年
  • 市場シェア分析、2024年
  • 企業評価マトリックス：主要参入企業、2024年
  • 企業評価マトリックス：スタートアップ/中小企業、2024年
  • 企業評価と財務指標
  • ブランド/製品比較
  • 競合シナリオ

第13章 企業プロファイル

  • 主要参入企業
    • KONINKLIJKE PHILIPS N.V.
    • F. HOFFMANN-LA ROCHE LTD.
    • HOLOGIC, INC.
    • AKOYA BIOSCIENCES, INC.
    • AIFORIA TECHNOLOGIES PLC
    • INDICA LABS INC.
    • OPTRASCAN
    • IBEX MEDICAL ANALYTICS LTD.
    • MINDPEAK GMBH
    • TRIBUN HEALTH
    • TECHCYTE, INC.
    • DEEP BIO INC.
    • LUMEA INC.
    • VISIOPHARM
    • AETHERAI
    • AIOSYN
    • PAIGE AI, INC.
    • PROSCIA, INC.
    • PATHAI, INC.
    • TEMPUS LABS, INC.
  • その他の企業
    • KONFOONG BIOINFORMATION TECH CO., LTD.
    • DOMORE DIAGNOSTICS AS
    • QRITIVE
    • DEEPATHOLOGY LTD
    • 4D PATH INC.

第14章 付録

図表

List of Tables

  • TABLE 1 EXCHANGE RATES, 2021-2024
  • TABLE 2 ROLE OF PLAYERS IN MARKET ECOSYSTEM
  • TABLE 3 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 4 US FDA: MEDICAL DEVICE CLASSIFICATION
  • TABLE 5 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
  • TABLE 6 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
  • TABLE 7 EUROPE: CLASSIFICATION OF IVD DEVICES
  • TABLE 8 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA
  • TABLE 9 CHINA: CLASSIFICATION OF MEDICAL DEVICES
  • TABLE 10 INDICATIVE PRICING ANALYSIS, BY OFFERING
  • TABLE 11 IMPACT OF PORTER'S FORCES
  • TABLE 12 JURISDICTION ANALYSIS OF TOP APPLICANTS IN AI IN PATHOLOGY MARKET
  • TABLE 13 KEY PATENTS IN AI IN PATHOLOGY MARKET
  • TABLE 14 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER (%)
  • TABLE 15 KEY BUYING CRITERIA, BY END USER
  • TABLE 16 UNMET NEEDS OF END USERS
  • TABLE 17 AI IN PATHOLOGY MARKET: END USER EXPECTATIONS
  • TABLE 18 LIST OF CONFERENCES AND EVENTS, 2025-2026
  • TABLE 19 IMPORT DATA FOR HS CODE 9011-COMPLIANT PRODUCTS, BY COUNTRY, 2020-2023 (USD THOUSAND)
  • TABLE 20 EXPORT DATA FOR HS CODE 9011-COMPLIANT PRODUCTS, BY COUNTRY, 2020-2023 (USD MILLION)
  • TABLE 21 RECIPROCAL TARIFF RATES ADJUSTED BY US
  • TABLE 22 TARIFF RATES FOR AI IN PATHOLOGY PRODUCTS
  • TABLE 23 EXPECTED CHANGE IN PRICES AND THEIR IMPACT ON END USER PRODUCTS DUE TO TARIFF IMPACT
  • TABLE 24 AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 25 AI IN PATHOLOGY MARKET FOR END-TO-END SOLUTIONS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 26 AI IN PATHOLOGY MARKET FOR NICHE POINT SOLUTIONS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 27 AI IN PATHOLOGY MARKET FOR TECHNOLOGY, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 28 AI IN PATHOLOGY MARKET FOR HARDWARE, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 29 AI IN PATHOLOGY MARKET FOR HARDWARE, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 30 AI IN PATHOLOGY MARKET FOR MICROSCOPES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 31 AI IN PATHOLOGY MARKET FOR SCANNERS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 32 AI IN PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 33 AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
  • TABLE 34 AI IN PATHOLOGY MARKET FOR CONVOLUTIONAL NEURAL NETWORKS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 35 AI IN PATHOLOGY MARKET FOR GENERATIVE ADVERSARIAL NETWORKS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 36 AI IN PATHOLOGY MARKET FOR RECURRENT NEURAL NETWORKS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 37 AI IN PATHOLOGY MARKET FOR OTHER NEURAL NETWORKS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 38 AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
  • TABLE 39 AI IN PATHOLOGY MARKET FOR IMAGE ANALYSIS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 40 AI IN PATHOLOGY MARKET FOR DIAGNOSTICS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 41 AI IN PATHOLOGY MARKET FOR WORKFLOW MANAGEMENT, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 42 AI IN PATHOLOGY MARKET FOR DATA MANAGEMENT, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 43 AI IN PATHOLOGY MARKET FOR PREDICTIVE ANALYTICS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 44 AI IN PATHOLOGY MARKET FOR CDSS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 45 AI IN PATHOLOGY MARKET FOR AUTOMATED REPORT GENERATION, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 46 AI IN PATHOLOGY MARKET FOR QUALITY ASSURANCE TOOLS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 47 AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 48 DRUG DISCOVERY APPLICATIONS FOR AI IN PATHOLOGY
  • TABLE 49 AI IN PATHOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 50 AI IN PATHOLOGY MARKET FOR DRUG DISCOVERY, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 51 AI IN PATHOLOGY MARKET FOR TARGET IDENTIFICATION & SELECTION, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 52 AI IN PATHOLOGY MARKET FOR TARGET VALIDATION, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 53 AI IN PATHOLOGY MARKET FOR HIT IDENTIFICATION & PRIORITIZATION, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 54 AI IN PATHOLOGY MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 55 AI IN PATHOLOGY MARKET FOR LEAD OPTIMIZATION, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 56 AI IN PATHOLOGY MARKET FOR CANDIDATE SELECTION & VALIDATION, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 57 AI IN PATHOLOGY MARKET FOR DISEASE DIAGNOSIS & PROGNOSIS, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 58 AI IN PATHOLOGY MARKET FOR CLINICAL WORKFLOW, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 59 AI IN PATHOLOGY MARKET FOR TRAINING & EDUCATION, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 60 AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 61 AI IN PATHOLOGY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 62 AI IN PATHOLOGY MARKET FOR HOSPITALS & REFERENCE LABORATORIES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 63 AI IN PATHOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 64 AI IN PATHOLOGY MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 65 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 66 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 67 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
  • TABLE 68 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
  • TABLE 69 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 70 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 71 US: AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 72 US: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
  • TABLE 73 US: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
  • TABLE 74 US: AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 75 US: AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 76 CANADA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 77 CANADA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
  • TABLE 78 CANADA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
  • TABLE 79 CANADA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 80 CANADA: AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 81 EUROPE: AI IN PATHOLOGY MARKET, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 82 EUROPE: AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 83 EUROPE: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
  • TABLE 84 EUROPE: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
  • TABLE 85 EUROPE: AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 86 EUROPE: AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 87 UK: AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 88 UK: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
  • TABLE 89 UK: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
  • TABLE 90 UK: AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 91 UK: AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 92 GERMANY: AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 93 GERMANY: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
  • TABLE 94 GERMANY: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
  • TABLE 95 GERMANY: AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 96 GERMANY: AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 97 FRANCE: AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 98 FRANCE: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
  • TABLE 99 FRANCE: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
  • TABLE 100 FRANCE: AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 101 FRANCE: AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 102 ITALY: AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 103 ITALY: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
  • TABLE 104 ITALY: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
  • TABLE 105 ITALY: AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 106 ITALY: AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 107 SPAIN: AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 108 SPAIN: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
  • TABLE 109 SPAIN: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
  • TABLE 110 SPAIN: AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 111 SPAIN: AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 112 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 113 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
  • TABLE 114 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
  • TABLE 115 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 116 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 117 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 118 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 119 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
  • TABLE 120 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
  • TABLE 121 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 122 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 123 CHINA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 124 CHINA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
  • TABLE 125 CHINA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
  • TABLE 126 CHINA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 127 CHINA: AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 128 JAPAN: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
  • TABLE 129 JAPAN: AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 130 JAPAN: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
  • TABLE 131 JAPAN: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
  • TABLE 132 JAPAN: AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 133 JAPAN: AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 134 INDIA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 135 INDIA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
  • TABLE 136 INDIA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
  • TABLE 137 INDIA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 138 INDIA: AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 139 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 140 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
  • TABLE 141 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
  • TABLE 142 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 143 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 144 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY COUNTRY/REGION, 2023-2030 (USD MILLION)
  • TABLE 145 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 146 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
  • TABLE 147 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
  • TABLE 148 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 149 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 150 BRAZIL: AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 151 BRAZIL: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
  • TABLE 152 BRAZIL: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
  • TABLE 153 BRAZIL: AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 154 BRAZIL: AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 155 MEXICO: AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 156 MEXICO: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
  • TABLE 157 MEXICO: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
  • TABLE 158 MEXICO: AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 159 MEXICO: AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 160 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 161 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
  • TABLE 162 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
  • TABLE 163 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 164 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 165 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 166 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 167 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
  • TABLE 168 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
  • TABLE 169 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 170 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 171 GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 172 GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
  • TABLE 173 GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
  • TABLE 174 GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 175 GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 176 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023-2030 (USD MILLION)
  • TABLE 177 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023-2030 (USD MILLION)
  • TABLE 178 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023-2030 (USD MILLION)
  • TABLE 179 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 180 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 181 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES
  • TABLE 182 AI IN PATHOLOGY MARKET: DEGREE OF COMPETITION
  • TABLE 183 OFFERING FOOTPRINT
  • TABLE 184 USE CASE FOOTPRINT
  • TABLE 185 END USER FOOTPRINT
  • TABLE 186 REGION FOOTPRINT
  • TABLE 187 AI IN PATHOLOGY MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 188 AI IN PATHOLOGY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • TABLE 189 AI IN PATHOLOGY MARKET: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-APRIL 2025
  • TABLE 190 AI IN PATHOLOGY MARKET: DEALS, JANUARY 2021-APRIL 2025
  • TABLE 191 AI IN PATHOLOGY MARKET: OTHER DEVELOPMENTS, JANUARY 2021- APRIL 2025
  • TABLE 192 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW
  • TABLE 193 KONINKLIJKE PHILIPS N.V.: PRODUCTS/SERVICES OFFERED
  • TABLE 194 KONINKLIJKE PHILIPS N.V.: DEALS, JANUARY 2021-APRIL 2025
  • TABLE 195 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
  • TABLE 196 F. HOFFMANN LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED
  • TABLE 197 F. HOFFMANN-LA ROCHE LTD.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-MARCH 2025
  • TABLE 198 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021-MARCH 2025
  • TABLE 199 HOLOGIC, INC.: COMPANY OVERVIEW
  • TABLE 200 HOLOGIC, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 201 HOLOGIC, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-APRIL 2025
  • TABLE 202 AKOYA BIOSCIENCES, INC.: COMPANY OVERVIEW
  • TABLE 203 AKOYA BIOSCIENCES, INC.: PRODUCT/SERVICES OFFERED
  • TABLE 204 AKOYA BIOSCIENCES, INC.: DEALS, JANUARY 2021-APRIL 2025
  • TABLE 205 AIFORIA TECHNOLOGIES PLC: COMPANY OVERVIEW
  • TABLE 206 AIFORIA TECHNOLOGIES PLC: PRODUCT/SERVICES OFFERED
  • TABLE 207 AIFORIA TECHNOLOGIES PLC: DEALS, JANUARY 2021-APRIL 2025
  • TABLE 208 INDICA LABS INC.: COMPANY OVERVIEW
  • TABLE 209 INDICA LABS INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 210 INDICA LABS INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-APRIL 2025
  • TABLE 211 INDICA LABS INC.: DEALS, JANUARY 2021-APRIL 2025
  • TABLE 212 INDICA LABS INC.: EXPANSIONS, JANUARY 2021-APRIL 2025
  • TABLE 213 OPTRASCAN: COMPANY OVERVIEW
  • TABLE 214 OPTRASCAN: PRODUCTS/SERVICES OFFERED
  • TABLE 215 OPTRASCAN: OTHER DEVELOPMENTS, JANUARY 2021-APRIL 2025
  • TABLE 216 IBEX MEDICAL ANALYTICS LTD.: COMPANY OVERVIEW
  • TABLE 217 IBEX MEDICAL ANALYTICS LTD.: PRODUCTS/SERVICES OFFERED
  • TABLE 218 IBEX MEDICAL ANALYTICS LTD.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-APRIL 2025
  • TABLE 219 IBEX MEDICAL ANALYTICS LTD: DEALS, JANUARY 2021-APRIL 2025
  • TABLE 220 MINDPEAK GMBH: COMPANY OVERVIEW
  • TABLE 221 MINDPEAK GMBH: PRODUCTS/SERVICES OFFERED
  • TABLE 222 MINDPEAK GMBH: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-APRIL 2025
  • TABLE 223 MINDPEAK GMBH: DEALS, JANUARY 2021-APRIL 2025
  • TABLE 224 MINDPEAK GMBH: OTHER DEVELOPMENTS, JANUARY 2021-APRIL 2025
  • TABLE 225 TRIBUN HEALTH: COMPANY OVERVIEW
  • TABLE 226 TRIBUN HEALTH: PRODUCTS/SERVICES OFFERED
  • TABLE 227 TRIBUN HEALTH: DEALS, JANUARY 2021-APRIL 2025
  • TABLE 228 TECHCYTE, INC.: COMPANY OVERVIEW
  • TABLE 229 TECHCYTE, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 230 TECHCYTE, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-APRIL 2025
  • TABLE 231 TECHCYTE, INC.: DEALS, JANUARY 2021-APRIL 2025
  • TABLE 232 TECHCYTE, INC.: OTHER DEVELOPMENTS, JANUARY 2021-APRIL 2025
  • TABLE 233 DEEP BIO INC.: COMPANY OVERVIEW
  • TABLE 234 DEEP BIO INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 235 DEEP BIO INC.: DEALS, JANUARY 2021-APRIL 2025
  • TABLE 236 LUMEA INC.: COMPANY OVERVIEW
  • TABLE 237 LUMEA INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 238 LUMEA INC.: DEALS, JANUARY 2021-APRIL 2025
  • TABLE 239 VISIOPHARM: COMPANY OVERVIEW
  • TABLE 240 VISIOPHARM: PRODUCTS/SERVICES OFFERED
  • TABLE 241 VISIOPHARM: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-APRIL 2025
  • TABLE 242 VISIOPHARM: EXPANSIONS, JANUARY 2021- APRIL 2025
  • TABLE 243 AETHERAI: COMPANY OVERVIEW
  • TABLE 244 AETHERAI: PRODUCTS/SERVICES OFFERED
  • TABLE 245 AETHERAI: DEALS, JANUARY 2021- APRIL 2025
  • TABLE 246 AIOSYN: COMPANY OVERVIEW
  • TABLE 247 AIOSYN: PRODUCTS/SERVICES OFFERED
  • TABLE 248 AIOSYN: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-APRIL 2025
  • TABLE 249 AIOSYN: DEALS, JANUARY 2021-APRIL 2025
  • TABLE 250 AIOSYN: OTHER DEVELOPMENTS, JANUARY 2021-APRIL 2025
  • TABLE 251 PAIGE AI, INC.: COMPANY OVERVIEW
  • TABLE 252 PAIGE AI, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 253 PAIGE AI, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021- APRIL 2025
  • TABLE 254 PAIGE AI, INC.: DEALS, JANUARY 2021-APRIL 2025
  • TABLE 255 PAIGE AI, INC.: OTHER DEVELOPMENTS, JANUARY 2021-APRIL 2025
  • TABLE 256 PROSCIA, INC.: COMPANY OVERVIEW
  • TABLE 257 PROSCIA, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 258 PROSCIA, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-APRIL 2025
  • TABLE 259 PROSCIA, INC.: DEALS, JANUARY 2021-APRIL 2025
  • TABLE 260 PROSCIA, INC.: OTHER DEVELOPMENTS, JANUARY 2021-APRIL 2025
  • TABLE 261 PATHAI, INC.: COMPANY OVERVIEW
  • TABLE 262 PATHAI, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 263 PATHAI, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-APRIL 2025
  • TABLE 264 PATHAI, INC.: DEALS, JANUARY 2021-APRIL 2025
  • TABLE 265 TEMPUS LABS, INC.: COMPANY OVERVIEW
  • TABLE 266 TEMPUS LABS, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 267 TEMPUS LABS, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-APRIL 2025
  • TABLE 268 KONFOONG BIOINFORMATION TECH CO., LTD.: COMPANY OVERVIEW
  • TABLE 269 DOMORE DIAGNOSTICS AS: COMPANY OVERVIEW
  • TABLE 270 QRITIVE: COMPANY OVERVIEW
  • TABLE 271 DEEPPATH: COMPANY OVERVIEW
  • TABLE 272 4D PATH INC.: COMPANY OVERVIEW

List of Figures

  • FIGURE 1 RESEARCH DESIGN
  • FIGURE 2 KEY PRIMARY SOURCES
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 4 MARKET SIZE ESTIMATION PROCESS
  • FIGURE 5 KEY INSIGHTS FROM INDUSTRY EXPERTS
  • FIGURE 6 BOTTOM-UP APPROACH: END USER SPENDING ON AI IN PATHOLOGY
  • FIGURE 7 AI IN PATHOLOGY MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2025-2030)
  • FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 9 TOP-DOWN APPROACH
  • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • FIGURE 11 AI IN PATHOLOGY MARKET, BY OFFERING, 2025 VS. 2030 (USD MILLION)
  • FIGURE 12 AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2025 VS. 2030 (USD MILLION)
  • FIGURE 13 AI IN PATHOLOGY MARKET, BY USE CASE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 14 AI IN PATHOLOGY MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
  • FIGURE 15 AI IN PATHOLOGY MARKET: GEOGRAPHIC SNAPSHOT
  • FIGURE 16 DEVELOPMENT OF CONVOLUTIONAL NEURAL NETWORKS (CNNS) AND AI LEARNING MODELS TO PROPEL MARKET
  • FIGURE 17 NORTH AMERICA TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 18 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES SEGMENT AND CHINA ACCOUNTED FOR SIGNIFICANT SHARE IN 2024
  • FIGURE 19 INDIA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 20 AI IN PATHOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 21 HEALTHCARE BREACHES REPORTED TO US DEPARTMENT OF HEALTH AND HUMAN SERVICES (SEPTEMBER 2024)
  • FIGURE 22 TRENDS & DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • FIGURE 23 ECOSYSTEM ANALYSIS
  • FIGURE 24 VALUE CHAIN ANALYSIS
  • FIGURE 25 EUROPE: IVDR TIMELINE
  • FIGURE 26 PORTER'S FIVE FORCES
  • FIGURE 27 NUMBER OF PATENTS PUBLISHED, JANUARY 2017-APRIL 2025
  • FIGURE 28 NUMBER OF PATENT DOCUMENTS, BY JURISDICTION
  • FIGURE 29 TOP PATENT APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS), JANUARY 2017-APRIL 2025
  • FIGURE 30 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER
  • FIGURE 31 KEY BUYING CRITERIA, BY END USER
  • FIGURE 32 FUNDING ACTIVITIES IN AI IN PATHOLOGY MARKET
  • FIGURE 33 MARKET POTENTIAL OF AI/GENERATIVE AI IN PATHOLOGY
  • FIGURE 34 IMPORT DATA FOR HS CODE 9011-COMPLIANT PRODUCTS, BY COUNTRY, 2020-2023 (USD)
  • FIGURE 35 EXPORT DATA FOR HS CODE 9011-COMPLIANT PRODUCTS, BY COUNTRY, 2020-2023 (USD THOUSAND)
  • FIGURE 36 NORTH AMERICA: AI IN PATHOLOGY MARKET SNAPSHOT
  • FIGURE 37 ASIA PACIFIC: AI IN PATHOLOGY MARKET SNAPSHOT
  • FIGURE 38 REVENUE ANALYSIS OF KEY PLAYERS, 2020-2024 (USD MILLION)
  • FIGURE 39 AI IN PATHOLOGY MARKET: MARKET SHARE ANALYSIS (2024)
  • FIGURE 40 AI IN PATHOLOGY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • FIGURE 41 AI IN PATHOLOGY MARKET: COMPANY FOOTPRINT
  • FIGURE 42 AI IN PATHOLOGY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • FIGURE 43 EV/EBITDA OF KEY VENDORS
  • FIGURE 44 YTD PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF AI IN PATHOLOGY VENDORS
  • FIGURE 45 BRAND/PRODUCT COMPARISON
  • FIGURE 46 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2024)
  • FIGURE 47 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024)
  • FIGURE 48 HOLOGIC, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 49 AKOYA BIOSCIENCES, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 50 AIFORIA TECHNOLOGIES PLC: COMPANY SNAPSHOT (2024)
  • FIGURE 51 TEMPUS: COMPANY SNAPSHOT (2024)
目次
Product Code: HIT 8721

The global AI in pathology market is expected to reach USD 347.39 million by 2030 from USD 107.43 million in 2025 at a high CAGR of 26.5% during the forecast period. According to the Personalized Medicine Coalition Report 2022, in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases. Among the newly approved treatments are seven cancer drugs and three targeting other diseases and conditions. About 47% of these approved personalized therapies were indicated for treating cancer.

Scope of the Report
Years Considered for the Study2024-2030
Base Year2024
Forecast Period2024-2030
Units ConsideredValue (USD billion)
SegmentsOffering, Neural Network, Function, Use Case, End User
Regions coveredNorth America, Europe, Asia Pacific, Latin America, and Middle East & Africa

By use case, the drug discovery segment accounted for the largest share in 2024.

In 2024, the drug discovery segment accounted for the largest share of the AI in pathology market. Booming pharmaceutical & biotechnology R&D expenditure, the growing high-throughput screening & imaging, the increasing use of AI algorithms in pathology image analysis for the identification & classification of diseases, and the capability of AI to speed up the development of new therapeutics are expected to boost the market.

In 2024, the pharmaceutical & biopharmaceutical companies segment accounted for the largest share of the AI in pathology market, by end user.

In 2024, the pharmaceutical & biopharmaceutical companies segment accounted for the largest market share due to advancements in drug discovery & development and the increasing use of AI in pathology for drug toxicology testing. Biotechnology companies use AI-based digital pathology for biobanking, biopharmaceutical studies, molecular assays, and the development of individualized medicine.

North America held the largest market share in 2024.

In 2024, North America accounted for the largest market share in the AI in pathology market due to strong investment in research & development and advanced healthcare infrastructure, which enables the use of high-tech machinery. The large patient pool and data availability help create a large database, which can be used to train the AI for higher accuracy and efficiency.

The breakdown of primary participants is as mentioned below:

  • By Company Type - Tier 1: 45%, Tier 2: 30%, and Tier 3: 25%
  • By Designation - C-level: 42%, Director-level: 31%, and Others: 27%
  • By Region - North America: 32%, Europe: 32%, Asia Pacific: 26%, Middle East & Africa: 5%, Latin America: 5%

Key Players

The key players in the AI in pathology market include Koninklijke Philips N.V. (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), Hologic, Inc. (US), Akoya Biosciences, Inc. (US), Aiforia Technologies Plc (Finland), Indica Labs Inc. (US), OptraScan (US), Ibex Medical Analytics Ltd. (Israel).

Research Coverage

The report estimates the market size and future growth potential of various market segments based on offering, neural network, use case, end user, function, and region. It also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report

This report will enrich established firms and new entrants/smaller firms to gauge the market's pulse, which, in turn, would help them garner a higher share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.

This report provides insights on:

  • Analysis of key drivers (development of CNNs and advanced AI models, Integration of AI into multiplex imaging, increasing cases of misdiagnoses in patients, benefits of AI-augmented telepathology, advancements in deep learning & image processing) restraints (high cost of digital pathology systems, limited AI expertise and varied regulatory guidelines for medical software, interoperability issues with legacy systems), opportunities (increasing demand for personalized medicine, integration of multi-omics data, and predictive analytics for disease progression) challenges (insufficient data for AI algorithms, data privacy, and ethical concerns, challenges associated with interpretability of AI models) influencing the growth of the AI in pathology market
  • Product Development/Innovation: Detailed insights into upcoming technologies, research & development activities, and new product & service launches in the AI in pathology market
  • Market Development: Comprehensive information on the lucrative emerging markets by offering, neural network, function, use case, end user, and region
  • Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKET SEGMENTATION AND GEOGRAPHIC SPREAD
    • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.4 YEARS CONSIDERED
  • 1.5 CURRENCY CONSIDERED
  • 1.6 KEY STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Revenue share analysis illustration
  • 2.2 MARKET SIZE ESTIMATION
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.4 RESEARCH ASSUMPTIONS
  • 2.5 RESEARCH LIMITATIONS
    • 2.5.1 METHODOLOGY-RELATED LIMITATIONS
    • 2.5.2 SCOPE-RELATED LIMITATIONS
  • 2.6 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 KEY OPPORTUNITIES FOR PLAYERS IN AI IN PATHOLOGY MARKET
  • 4.2 AI IN PATHOLOGY MARKET: REGIONAL MIX
  • 4.3 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY END USER AND KEY COUNTRY/REGION
  • 4.4 GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Development of CNNs and advanced AI models
      • 5.2.1.2 Integration of AI into multiplex imaging
      • 5.2.1.3 Increasing cases of misdiagnoses in patients
      • 5.2.1.4 Benefits of AI-augmented telepathology
      • 5.2.1.5 Advancements in deep learning & image processing
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High cost of digital pathology systems
      • 5.2.2.2 Limited AI expertise and varied regulatory guidelines for medical software
      • 5.2.2.3 Inadequate interoperability issues with legacy systems
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Increasing demand for personalized medicines
      • 5.2.3.2 Integration of multi-omics data
      • 5.2.3.3 Predictive analytics for disease progression
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Insufficient data for AI algorithms
      • 5.2.4.2 Data privacy and ethical concerns
      • 5.2.4.3 Challenges associated with interpretability of AI models
  • 5.3 TRENDS & DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.4 INDUSTRY TRENDS
    • 5.4.1 EVOLUTION OF AI IN PATHOLOGY
  • 5.5 ECOSYSTEM ANALYSIS
  • 5.6 VALUE CHAIN ANALYSIS
  • 5.7 TECHNOLOGY ANALYSIS
    • 5.7.1 KEY TECHNOLOGIES
      • 5.7.1.1 Machine learning (ML) and artificial intelligence (AI)
      • 5.7.1.2 Computer vision
    • 5.7.2 COMPLEMENTARY TECHNOLOGIES
      • 5.7.2.1 Cloud computing
    • 5.7.3 ADJACENT TECHNOLOGIES
      • 5.7.3.1 Telepathology
  • 5.8 REGULATORY LANDSCAPE
    • 5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.8.2 REGULATIONS, BY REGION
      • 5.8.2.1 North America
        • 5.8.2.1.1 US
        • 5.8.2.1.2 Canada
      • 5.8.2.2 Europe
      • 5.8.2.3 Asia Pacific
        • 5.8.2.3.1 Japan
        • 5.8.2.3.2 China
  • 5.9 PRICING ANALYSIS
    • 5.9.1 AVERAGE SELLING PRICE TREND, BY REGION
    • 5.9.2 INDICATIVE PRICING ANALYSIS, BY OFFERING
  • 5.10 PORTER'S FIVE FORCES ANALYSIS
    • 5.10.1 THREAT FROM NEW ENTRANTS
    • 5.10.2 THREAT FROM SUBSTITUTES
    • 5.10.3 BARGAINING POWER OF SUPPLIERS
    • 5.10.4 BARGAINING POWER OF BUYERS
    • 5.10.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.11 PATENT ANALYSIS
    • 5.11.1 PATENT PUBLICATION TRENDS FOR AI IN PATHOLOGY SOLUTIONS
    • 5.11.2 JURISDICTION AND TOP APPLICANT ANALYSIS
  • 5.12 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.12.2 BUYING CRITERIA
  • 5.13 END USER ANALYSIS
    • 5.13.1 UNMET NEEDS OF END USERS
    • 5.13.2 END USER EXPECTATIONS
  • 5.14 KEY CONFERENCES AND EVENTS, 2025-2026
  • 5.15 CASE STUDY ANALYSIS
    • 5.15.1 CASE STUDY 1: PATBAL EMPLOYED PYTORCH FOR ITS HIGH-LEVEL PYTHONIC SYNTAX TO SUPPORT DIVERSE MODELING APPROACHES
    • 5.15.2 CASE STUDY 2: KFBIO DEVELOPED KFBIO AI CERVICAL CANCER SCREENING SYSTEM TO STRENGTHEN CANCER DIAGNOSIS
    • 5.15.3 CASE STUDY 3: RESEARCH TEAM FROM UNIVERSITY OF HELSINKI USED AIFORIA CREATE TO DEVELOP DEEP-LEARNING AI MODEL TO PREDICT PATIENT OUTCOMES
  • 5.16 INVESTMENT & FUNDING SCENARIO
  • 5.17 BUSINESS MODELS
  • 5.18 IMPACT OF AI/GEN AI ON AI IN PATHOLOGY MARKET
    • 5.18.1 KEY USE CASES
    • 5.18.2 AI/GENERATIVE AI IMPLEMENTATION: CASE STUDY
      • 5.18.2.1 Accelerated biomarker discovery and clinical trial optimization
    • 5.18.3 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
      • 5.18.3.1 Drug discovery & development market
      • 5.18.3.2 Medical imaging & diagnostics market
    • 5.18.4 USER READINESS AND IMPACT ASSESSMENT
      • 5.18.4.1 User readiness
        • 5.18.4.1.1 Pharmaceutical companies
        • 5.18.4.1.2 Biopharmaceutical companies
      • 5.18.4.2 Impact assessment
        • 5.18.4.2.1 User A: Pharmaceutical companies
          • 5.18.4.2.1.1 Implementation
          • 5.18.4.2.1.2 Impact
        • 5.18.4.2.2 User B: Biopharmaceutical companies
          • 5.18.4.2.2.1 Implementation
          • 5.18.4.2.2.2 Impact
  • 5.19 TRADE ANALYSIS
    • 5.19.1 IMPORT SCENARIO
    • 5.19.2 EXPORT SCENARIO
  • 5.20 US 2025 TARIFF
    • 5.20.1 INTRODUCTION
    • 5.20.2 KEY TARIFF RATES
    • 5.20.3 PRICE IMPACT ANALYSIS
    • 5.20.4 IMPACT ON COUNTRY/REGION
      • 5.20.4.1 US
      • 5.20.4.2 Europe
      • 5.20.4.3 Asia Pacific
    • 5.20.5 IMPACT ON END USE INDUSTRIES

6 AI IN PATHOLOGY MARKET, BY OFFERING

  • 6.1 INTRODUCTION
  • 6.2 END-TO-END SOLUTIONS
    • 6.2.1 INCREASING DEMAND FOR INTEGRATED WORKFLOWS IN HEALTHCARE MODELS TO DRIVE MARKET
  • 6.3 NICHE POINT SOLUTIONS
    • 6.3.1 GROWING FOCUS ON PRECISION MEDICINE AND TARGETED THERAPY RESEARCH TO PROPEL MARKET
  • 6.4 TECHNOLOGY
    • 6.4.1 RISING NEED FOR ADVANCED DATA MANAGEMENT SOLUTIONS TO FUEL MARKET
  • 6.5 HARDWARE
    • 6.5.1 HIGH ADOPTION OF AI-BASED MICROSCOPES TO PROPEL MARKET
  • 6.6 MICROSCOPES
    • 6.6.1 NEED FOR AUTOMATED ANALYSIS OF TISSUE SAMPLES TO FUEL GROWTH
  • 6.7 SCANNERS
    • 6.7.1 IMPROVEMENTS IN IMAGE QUALITY AND PRECISION DIAGNOSTICS TO BOOST DEMAND
  • 6.8 STORAGE SYSTEMS
    • 6.8.1 NEED FOR STRUCTURED MODELS OF HIGH-RESOLUTION IMAGES TO SUPPORT MARKET GROWTH

7 AI IN PATHOLOGY MARKET, BY NEURAL NETWORK

  • 7.1 INTRODUCTION
  • 7.2 CONVOLUTIONAL NEURAL NETWORKS (CNNS)
    • 7.2.1 FOCUS ON PROVIDING HIGH-QUALITY IMAGE RECOGNITION AND OBJECTION DETECTION TO PROPEL MARKET
  • 7.3 GENERATIVE ADVERSARIAL NETWORKS (GANS)
    • 7.3.1 NEED FOR GENERATING ACCURATE SYNTHETIC PATHOLOGY IMAGES TO DRIVE MARKET
  • 7.4 RECURRENT NEURAL NETWORKS (RNNS)
    • 7.4.1 NEED FOR ANALYSIS OF SEQUENTIAL DATA AND TIME-DEPENDENT PATTERNS TO FUEL MARKET
  • 7.5 OTHER NEURAL NETWORKS

8 AI IN PATHOLOGY MARKET, BY FUNCTION

  • 8.1 INTRODUCTION
  • 8.2 IMAGE ANALYSIS
    • 8.2.1 DETECTION OF CELLULAR ANOMALIES AND DISEASE MARKERS TO FUEL UPTAKE
  • 8.3 DIAGNOSTICS
    • 8.3.1 RAPID PROCESSION OF AUTOMATED SAMPLES TO DRIVE MARKET
  • 8.4 WORKFLOW MANAGEMENT
    • 8.4.1 OPTIMIZATION OF LAB RESOURCES FOR HIGH-THROUGHPUT RESULTS TO FUEL UPTAKE
  • 8.5 DATA MANAGEMENT
    • 8.5.1 EMPHASIS ON ADVANCEMENTS IN DATA INTEGRATION AND PROCESSING TO BOOST DEMAND
  • 8.6 PREDICTIVE ANALYTICS
    • 8.6.1 GROWING FOCUS ON EARLY DIAGNOSIS OF DISEASES TO DRIVE MARKET
  • 8.7 CDSS
    • 8.7.1 PROVISION OF REAL-TIME INSIGHTS TO FUEL MARKET
  • 8.8 AUTOMATED REPORT GENERATION
    • 8.8.1 INCREASING DEMAND FOR QUALITY CONTROL TO DRIVE MARKET
  • 8.9 QUALITY ASSURANCE TOOLS
    • 8.9.1 RISING REGULATORY NEED TO ACCELERATE DEMAND FOR QUALITY ASSURANCE TOOLS TO BOOST GROWTH

9 AI IN PATHOLOGY MARKET, BY USE CASE

  • 9.1 INTRODUCTION
  • 9.2 DRUG DISCOVERY
    • 9.2.1 TARGET IDENTIFICATION & SELECTION
      • 9.2.1.1 Analysis of molecular and histological data for biomarker discovery to fuel market
    • 9.2.2 TARGET VALIDATION
      • 9.2.2.1 Increasing demand for precision medicines to drive market
    • 9.2.3 HIT IDENTIFICATION & PRIORITIZATION
      • 9.2.3.1 Growing requirement for rapid analysis and cost efficiency to fuel uptake
    • 9.2.4 HIT-TO-LEAD IDENTIFICATION
      • 9.2.4.1 Advancements in ML to support market growth
    • 9.2.5 LEAD OPTIMIZATION
      • 9.2.5.1 Growing focus on therapeutic efficacy to propel market
    • 9.2.6 CANDIDATE SELECTION & VALIDATION
      • 9.2.6.1 Critical requirement for regulatory approvals to drive market
  • 9.3 DISEASE DIAGNOSIS & PROGNOSIS
    • 9.3.1 INCREASING INCIDENCE OF CHRONIC DISEASES TO FUEL MARKET
  • 9.4 CLINICAL WORKFLOW
    • 9.4.1 STRUCTURED AUTOMATION OF EXTENSIVE VOLUME DATA TO DRIVE MARKET
  • 9.5 TRAINING & EDUCATION
    • 9.5.1 UTILIZATION OF DIGITAL PATHOLOGY SYSTEMS IN ACADEMIC INSTITUTES TO SUPPORT MARKET GROWTH

10 AI IN PATHOLOGY MARKET, BY END USER

  • 10.1 INTRODUCTION
  • 10.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
    • 10.2.1 GROWING FOCUS ON TOXICOLOGY TESTING TO PROPEL MARKET
  • 10.3 HOSPITALS & REFERENCE LABORATORIES
    • 10.3.1 INCREASING NEED FOR EFFECTIVE DIAGNOSES OF INFECTIOUS DISEASES TO DRIVE GROWTH
  • 10.4 ACADEMIC & RESEARCH INSTITUTES
    • 10.4.1 GROWING INVESTMENTS IN LIFE SCIENCES RESEARCH TO SUPPORT DEMAND

11 AI IN PATHOLOGY MARKET, BY REGION

  • 11.1 INTRODUCTION
  • 11.2 NORTH AMERICA
    • 11.2.1 MACROECONOMIC OUTLOOK
    • 11.2.2 US
      • 11.2.2.1 High healthcare expenditure and improvements in cloud computing platforms to propel market
    • 11.2.3 CANADA
      • 11.2.3.1 Increasing adoption of deep learning for advanced healthcare diagnostics to drive market
  • 11.3 EUROPE
    • 11.3.1 MACROECONOMIC OUTLOOK
    • 11.3.2 UK
      • 11.3.2.1 Increased focus on drug discovery and development to boost demand
    • 11.3.3 GERMANY
      • 11.3.3.1 Availability of funding for AI initiatives to fuel uptake
    • 11.3.4 FRANCE
      • 11.3.4.1 Increasing adoption of big data in healthcare computing to fuel uptake
    • 11.3.5 ITALY
      • 11.3.5.1 Digital transformation and innovation in healthcare to support market growth
    • 11.3.6 SPAIN
      • 11.3.6.1 Increased workforce shortage to fuel market
    • 11.3.7 REST OF EUROPE
  • 11.4 ASIA PACIFIC
    • 11.4.1 MACROECONOMIC OUTLOOK
    • 11.4.2 CHINA
      • 11.4.2.1 Rising cases of infectious and chronic diseases to fuel demand
    • 11.4.3 JAPAN
      • 11.4.3.1 Advanced healthcare infrastructure to propel market
    • 11.4.4 INDIA
      • 11.4.4.1 Growing focus on healthcare digitization to boost demand
    • 11.4.5 REST OF ASIA PACIFIC
  • 11.5 LATIN AMERICA
    • 11.5.1 MACROECONOMIC OUTLOOK
    • 11.5.2 BRAZIL
      • 11.5.2.1 Strategic investments for AI adoption to support market growth
    • 11.5.3 MEXICO
      • 11.5.3.1 Growth in pharmaceutical R&D to drive market
    • 11.5.4 REST OF LATIN AMERICA
  • 11.6 MIDDLE EAST & AFRICA
    • 11.6.1 MACROECONOMIC OUTLOOK
    • 11.6.2 GCC COUNTRIES
      • 11.6.2.1 Increasing investments for expansion of technological expertise to support growth
    • 11.6.3 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

  • 12.1 INTRODUCTION
  • 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AI IN PATHOLOGY MARKET
  • 12.3 REVENUE ANALYSIS, 2020-2024
  • 12.4 MARKET SHARE ANALYSIS, 2024
  • 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    • 12.5.1 STARS
    • 12.5.2 EMERGING LEADERS
    • 12.5.3 PERVASIVE PLAYERS
    • 12.5.4 PARTICIPANTS
    • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
      • 12.5.5.1 Company footprint
      • 12.5.5.2 Offering footprint
      • 12.5.5.3 Use case footprint
      • 12.5.5.4 End user footprint
      • 12.5.5.5 Region footprint
  • 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    • 12.6.1 PROGRESSIVE COMPANIES
    • 12.6.2 RESPONSIVE COMPANIES
    • 12.6.3 DYNAMIC COMPANIES
    • 12.6.4 STARTING BLOCKS
    • 12.6.5 COMPETITIVE BENCHMARKING
  • 12.7 COMPANY VALUATION & FINANCIAL METRICS
    • 12.7.1 FINANCIAL METRICS
    • 12.7.2 COMPANY VALUATION
  • 12.8 BRAND/PRODUCT COMPARISON
  • 12.9 COMPETITIVE SCENARIO
    • 12.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS
    • 12.9.2 DEALS
    • 12.9.3 OTHER DEVELOPMENTS

13 COMPANY PROFILES

  • 13.1 KEY PLAYERS
    • 13.1.1 KONINKLIJKE PHILIPS N.V.
      • 13.1.1.1 Business overview
      • 13.1.1.2 Products/Services offered
      • 13.1.1.3 Recent developments
        • 13.1.1.3.1 Deals
      • 13.1.1.4 MnM view
        • 13.1.1.4.1 Key strengths
        • 13.1.1.4.2 Strategic choices
        • 13.1.1.4.3 Weaknesses & competitive threats
    • 13.1.2 F. HOFFMANN-LA ROCHE LTD.
      • 13.1.2.1 Business overview
      • 13.1.2.2 Products/Services offered
      • 13.1.2.3 Recent developments
        • 13.1.2.3.1 Product/Service launches & approvals
        • 13.1.2.3.2 Deals
      • 13.1.2.4 MnM view
        • 13.1.2.4.1 Key strengths
        • 13.1.2.4.2 Strategic choices
        • 13.1.2.4.3 Weaknesses & competitive threats
    • 13.1.3 HOLOGIC, INC.
      • 13.1.3.1 Business overview
      • 13.1.3.2 Products/Services offered
      • 13.1.3.3 Recent developments
        • 13.1.3.3.1 Product/Service launches & approvals
      • 13.1.3.4 MnM view
        • 13.1.3.4.1 Key strengths
        • 13.1.3.4.2 Strategic choices
        • 13.1.3.4.3 Weaknesses & competitive threats
    • 13.1.4 AKOYA BIOSCIENCES, INC.
      • 13.1.4.1 Business overview
      • 13.1.4.2 Products/Services offered
      • 13.1.4.3 Recent developments
        • 13.1.4.3.1 Deals
      • 13.1.4.4 MnM view
        • 13.1.4.4.1 Key strengths
        • 13.1.4.4.2 Strategic choices
        • 13.1.4.4.3 Weaknesses & competitive threats
    • 13.1.5 AIFORIA TECHNOLOGIES PLC
      • 13.1.5.1 Business overview
      • 13.1.5.2 Products/Services offered
      • 13.1.5.3 Recent developments
        • 13.1.5.3.1 Deals
      • 13.1.5.4 MnM view
        • 13.1.5.4.1 Key strengths
        • 13.1.5.4.2 Strategic choices
        • 13.1.5.4.3 Weaknesses & competitive threats
    • 13.1.6 INDICA LABS INC.
      • 13.1.6.1 Business overview
      • 13.1.6.2 Products/Services offered
      • 13.1.6.3 Recent developments
        • 13.1.6.3.1 Product/Service launches & approvals
        • 13.1.6.3.2 Deals
        • 13.1.6.3.3 Expansions
    • 13.1.7 OPTRASCAN
      • 13.1.7.1 Business overview
      • 13.1.7.2 Products/Services offered
      • 13.1.7.3 Recent developments
        • 13.1.7.3.1 Other developments
    • 13.1.8 IBEX MEDICAL ANALYTICS LTD.
      • 13.1.8.1 Business overview
      • 13.1.8.2 Products/Services offered
      • 13.1.8.3 Recent developments
        • 13.1.8.3.1 Product/Service launches & approvals
        • 13.1.8.3.2 Deals
    • 13.1.9 MINDPEAK GMBH
      • 13.1.9.1 Business overview
      • 13.1.9.2 Products/Services offered
      • 13.1.9.3 Recent developments
        • 13.1.9.3.1 Product/Service launches & approvals
        • 13.1.9.3.2 Deals
        • 13.1.9.3.3 Other developments
    • 13.1.10 TRIBUN HEALTH
      • 13.1.10.1 Business overview
      • 13.1.10.2 Products/Services offered
      • 13.1.10.3 Recent developments
        • 13.1.10.3.1 Deals
    • 13.1.11 TECHCYTE, INC.
      • 13.1.11.1 Business overview
      • 13.1.11.2 Products/Services offered
      • 13.1.11.3 Recent developments
        • 13.1.11.3.1 Product/Service launches & approvals
        • 13.1.11.3.2 Deals
        • 13.1.11.3.3 Other developments
    • 13.1.12 DEEP BIO INC.
      • 13.1.12.1 Business overview
      • 13.1.12.2 Products/Services offered
      • 13.1.12.3 Recent developments
        • 13.1.12.3.1 Deals
    • 13.1.13 LUMEA INC.
      • 13.1.13.1 Business overview
      • 13.1.13.2 Products/Services offered
      • 13.1.13.3 Recent developments
        • 13.1.13.3.1 Deals
    • 13.1.14 VISIOPHARM
      • 13.1.14.1 Business overview
      • 13.1.14.2 Products/Services offered
      • 13.1.14.3 Recent developments
        • 13.1.14.3.1 Product/Service launches & approvals
        • 13.1.14.3.2 Expansions
    • 13.1.15 AETHERAI
      • 13.1.15.1 Business overview
      • 13.1.15.2 Products/Services offered
      • 13.1.15.3 Recent developments
        • 13.1.15.3.1 Deals
    • 13.1.16 AIOSYN
      • 13.1.16.1 Business overview
      • 13.1.16.2 Products/Services offered
      • 13.1.16.3 Recent developments
        • 13.1.16.3.1 Product/Service launches & approvals
        • 13.1.16.3.2 Deals
        • 13.1.16.3.3 Other developments
    • 13.1.17 PAIGE AI, INC.
      • 13.1.17.1 Business overview
      • 13.1.17.2 Products/Services offered
      • 13.1.17.3 Recent developments
        • 13.1.17.3.1 Product/Service launches & approvals
        • 13.1.17.3.2 Deals
        • 13.1.17.3.3 Other developments
    • 13.1.18 PROSCIA, INC.
      • 13.1.18.1 Business overview
      • 13.1.18.2 Products/Services offered
      • 13.1.18.3 Recent developments
        • 13.1.18.3.1 Product/Service launches & approvals
        • 13.1.18.3.2 Deals
        • 13.1.18.3.3 Other developments
    • 13.1.19 PATHAI, INC.
      • 13.1.19.1 Business overview
      • 13.1.19.2 Products/Services offered
      • 13.1.19.3 Recent developments
        • 13.1.19.3.1 Product/Service launches & approvals
        • 13.1.19.3.2 Deals
    • 13.1.20 TEMPUS LABS, INC.
      • 13.1.20.1 Business overview
      • 13.1.20.2 Products/Services offered
      • 13.1.20.3 Recent developments
        • 13.1.20.3.1 Product/Service launches & approvals
  • 13.2 OTHER PLAYERS
    • 13.2.1 KONFOONG BIOINFORMATION TECH CO., LTD.
    • 13.2.2 DOMORE DIAGNOSTICS AS
    • 13.2.3 QRITIVE
    • 13.2.4 DEEPATHOLOGY LTD
    • 13.2.5 4D PATH INC.

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS